Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657342 | PMC |
| http://dx.doi.org/10.1111/jdv.17614 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High coverage and equitable distribution of COVID-19 vaccine uptake in two vulnerable areas in Bangladesh.
PLOS Glob Public Health
January 2025
CEPED, IRD-Université de Paris, ERL INSERM SAGESUD, Paris, France.
Bangladesh completed a primary series of COVID-19 vaccinations for about 86 individuals per 100 population as of 5 July 2023. However, ensuring higher coverage in vulnerable areas is challenging. We report on the COVID-19 vaccine uptake and associated factors among adults in two vulnerable areas in Bangladesh.
View Article and Find Full Text PDFEffect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
PLoS Med
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.
View Article and Find Full Text PDFProtocol for evaluating humoral immune responses in mice following SARS-CoV-2 vaccination.
STAR Protoc
January 2025
Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China; State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China. Electronic address:
Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.
View Article and Find Full Text PDFConsequences and Opportunities From Poor Uptake of COVID Vaccinations Despite Strong Evidence.
JAMA
January 2025
US Food and Drug Administration, Silver Spring, Maryland.
The Second Round of a Population-Based Seroprevalence Study of Anti-SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina.
Influenza Other Respir Viruses
January 2025
Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, Republika Srpska, Bosnia and Herzegovina.
Introduction: The aim of the study was to assess the seroprevalence of SARS-CoV-2 in the Republika Srpska, Bosnia and Herzegovina, after five waves of COVID-19 and 1 year after introduction of vaccination to better understand the true extent of the COVID-19 pandemic in the population of the Republika Srpska and role of vaccination in achieving herd immunity.
Methods: The population-based study was conducted from December 2021 to February 2022 in a group of 4463 individuals in the Republika Srpska. Total anti-SARS-CoV-2 antibodies were determined in serum specimens using the Wantai total antibody ELISA assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!